Alnylam Posts Another Encouraging Quarter Early In Onpattro's Launch

As difficult as it is to get a drug from the lab to the market, that's only part of the formula for success for biotechs - successful commercialization is every bit as important, and commercialization can have its own frustrating bumps along the road. While I see nothing wrong with the launch trajectory of Alnylam's (ALNY) Onpattro, it would seem that investors were spooked by quarter-to-quarter lumpiness in some of the launch metrics.

I continue to believe Alnylam is an appealing albeit high-risk investment opportunity. Onpattro is off to a good start, and the company should see a series of needle-moving regulatory approvals and commercial launches over the next few years, with more than a couple drugs holding $1 billion-plus revenue potential.

Follow this link to the rest of the article:
Alnylam Posts Another Encouraging Quarter Early In Onpattro's Launch